Using B cell features to explain heterogeneity in the rate of T1D progression

Information

  • Research Project
  • 10264100
  • ApplicationId
    10264100
  • Core Project Number
    R03DK127475
  • Full Project Number
    5R03DK127475-02
  • Serial Number
    127475
  • FOA Number
    RFA-DK-19-026
  • Sub Project Id
  • Project Start Date
    9/15/2020 - 4 years ago
  • Project End Date
    8/31/2022 - 2 years ago
  • Program Officer Name
    SPAIN, LISA M
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    7/28/2021 - 3 years ago

Using B cell features to explain heterogeneity in the rate of T1D progression

Project Summary / Abstract The overall goal for this Gateway Award is to evaluate B cell endotypes and examine how an endotype may be associated with T1D progression in autoantibody-positive individuals. Importantly, this award will provide an opportunity for the PI, as an Early Stage Investigator, to formally collaborate with Type 1 Diabetes TrialNet. The natural history of T1D is well understood, progressing from genetic risk, to autoimmunity, to clinical disease, and then to further ongoing loss of beta cell function. However, each step of this progression, as well as response to disease modifying immune therapy, is characterized by considerable heterogeneity. Much of our own work has aimed to identify immune markers that explain this heterogeneity; we recently showed that more rapid disease progression after diagnosis was evident in younger subjects with an increased B cell signature, and that this same signature predicted response to a B-cell targeting drug. Together, these findings suggest that B cells play an important role in some individuals with T1D. We propose that B cell characteristics may identify an endotype, or underlying disease mechanism of T1D that may be selectively targeted therapeutically, and that this can be seen in at-risk individuals as it was in the new onset setting. Despite these findings, there remain significant gaps in knowledge. First, can B cell endotypes observed after diagnosis explain heterogeneity in rate of progression from antibody positivity to clinical T1D? It is also unknown whether B cell endotypes are fixed characteristics of individuals or change as disease changes. Finally, it is likely that as-yet unidentified subpopulations of B cells, rather than the total population, mechanistically explain these findings. To address these gaps, we propose to address the hypothesis that B cell levels and signatures constitute a stable endotype prior to clinical diagnosis of T1D which will be associated with progression to T1D in the subset of subjects bearing this endotype.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R03
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    100000
  • Indirect Cost Amount
    74100
  • Total Cost
    174100
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:174100\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BENAROYA RESEARCH INST AT VIRGINIA MASON
  • Organization Department
  • Organization DUNS
    076647908
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981012795
  • Organization District
    UNITED STATES